Furthermore, it has been confirmed in melanoma, GC, and NSCLC that patients with low baseline peripheral blood exo-PD-L1 levels usually have complete or partial responses to PD-1/PD-L1 inhibitor therapy [86–88]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.